ESO-T01 for returning or hard-to-treat multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new treatment called ESO-T01 for people with multiple myeloma that has come back or is not responding to at least two prior therapies. It aims to see if this therapy is safe and can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older with a confirmed diagnosis of multiple myeloma that shows a protein called BCMA on the cancer cells.
- You must have already tried at least two different treatments for myeloma, and your disease has gotten worse within the past 12 months or is not responding to key drugs like immunomodulators and proteasome inhibitors.
- Your disease must be measurable, meaning you have enough M-proteins or abnormal light chains in your blood or urine.
- You must be in fairly good health, with an ECOG performance status of 0 to 2, meaning you are up and about at least half the day.
- Your blood counts (hemoglobin, white cells, platelets) and organ functions (kidneys, liver, heart, lungs) must meet specific levels to be safe for the trial.
- You cannot have certain active infections, other cancers, or conditions like heart failure, and you must not be pregnant or planning to donate eggs or sperm.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins, BCMA and GPRC5D, on myeloma cells. It aims to see if it is safe and effective for people whose multiple myeloma has come back or stopped responding to at least three previous treatments.
This trial is testing a new cell therapy (called Eque-cel) for people with multiple myeloma that has come back or stopped responding to standard treatments. The therapy uses your own immune cells to attack the myeloma cells. You may qualify if you've tried at least three prior treatment combinations.
This trial tests a new drug called QI-019A for people whose multiple myeloma has returned or stopped responding to at least two prior treatments. The goal is to see if it is safe and if it can help control the disease.
This trial tests a new experimental drug called CM336 for people with multiple myeloma that has come back or stopped responding to standard treatments. The drug may work by helping your immune system attack and destroy myeloma cells. If you join, you will receive the study treatment and be closely monitored to see how well it works and how safe it is.
This study tests a new drug called elranatamab for people with multiple myeloma that has come back or not responded to previous treatments. Elranatamab is a type of immunotherapy that targets a protein on myeloma cells to help your immune system fight the cancer.
This trial tests a new treatment combination for multiple myeloma that has returned or stopped responding to previous therapy and has spread outside the bone marrow. It aims to see if the combination can shrink these tumors and improve outcomes.
Hear when a new Relapsed/Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.